PHF2 and metabolic dysfunction-associated steatotic liver disease: Taking into account Phf2 expression and activity as a reliable biomarker, our study could also lead to disease stratification, from simple steatosis to NASH and fibrosis, providing new tracks in NAFLD pathogenesis.